Clinical trial
A Multi-Center, Double-Blind, Randomized, Phase III Study to Investigate the Efficacy and Safety of CS1001 in Combination With Fluorouracil and Cisplatin (FP) Compared to Placebo in Combination With FP as First-Line Therapy in Subjects With Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)
NCT04187352 is registered in ClinicalTrials.gov with CStone Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-Center, Double-Blind, Randomized, Phase III Study to Investigate the Efficacy and Safety of CS1001 in Combination With Fluorouracil and Cisplatin (FP) Compared to Placebo in Combination With FP as First-Line Therapy in Subjects With Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)
- Lead sponsor
- CStone Pharmaceuticals
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 19, 2019
- Completion date
- October 7, 2022
- Enrollment
- 540 (actual)
- Sites
- 72
Conditions
As the registry lists them; a condition with its own page is linked.
unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma